Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder

NCT01738087 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthmatic

Interventions

DRUG: NEXThaler 100/6 mcg DPI
DRUG: Flixotide Accuhaler 500 mcg
DRUG: NEXThaler 200/6 mcg DPI
DRUG: NEXThaler placebo

Sponsor

Chiesi Farmaceutici S.p.A.